Financhill
Sell
36

BPMC Quote, Financials, Valuation and Earnings

Last price:
$92.23
Seasonality move :
3.76%
Day range:
$91.71 - $95.60
52-week range:
$80.68 - $121.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.50x
P/B ratio:
19.74x
Volume:
777.2K
Avg. volume:
1.1M
1-year change:
5.72%
Market cap:
$5.9B
Revenue:
$508.8M
EPS (TTM):
-$1.08

Analysts' Opinion

  • Consensus Rating
    Blueprint Medicines has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 5 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $126.79, Blueprint Medicines has an estimated upside of 37.44% from its current price of $92.25.
  • Price Target Downside
    According to analysts, the lowest downside price target is $83.00 representing 10.03% downside risk from its current price of $92.25.

Fair Value

  • According to the consensus of 15 analysts, Blueprint Medicines has 37.44% upside to fair value with a price target of $126.79 per share.

BPMC vs. S&P 500

  • Over the past 5 trading days, Blueprint Medicines has underperformed the S&P 500 by -1.45% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Blueprint Medicines does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Blueprint Medicines has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Blueprint Medicines reported revenues of $146.4M.

Earnings Growth

  • Blueprint Medicines has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Blueprint Medicines reported earnings per share of -$0.79.
Enterprise value:
5.7B
EV / Invested capital:
8.27x
Price / LTM sales:
11.50x
EV / EBIT:
1,924.87x
EV / Revenue:
11.14x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-28.73x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
294.61x
Gross Profit (TTM):
$488.7M
Return On Assets:
-5.92%
Net Income Margin (TTM):
-13.19%
Return On Equity:
-24.43%
Return On Invested Capital:
-11.14%
Operating Margin:
-28.15%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $204M $249.4M $508.8M $72M $146.4M
Gross Profit $186.2M $240.8M $488.7M $71.7M $138.9M
Operating Income -$528.6M -$482M -$212M -$105.2M -$41.2M
EBITDA -$513.6M -$442.7M $19.2M -$94.3M -$27.1M
Diluted EPS -$9.35 -$8.36 -$1.08 -$1.82 -$0.79
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $927.8M $554M $1B $808.4M $742.7M
Total Assets $1.7B $1.3B $1.3B $1B $1.2B
Current Liabilities $130.8M $149.8M $183.2M $214.9M $260.8M
Total Liabilities $248.3M $281.5M $835.2M $918.6M $881.1M
Total Equity $1.5B $970.7M $514.7M $130.6M $298.7M
Total Debt -- -- $139.1M $238.8M $387M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations -$502.3M -$436.8M -$192.6M -$78.9M -$29.4M
Cash From Investing -$149.5M $274M -$47.5M $78.8M $33.7M
Cash From Financing $561.8M $119.2M $273.1M $15.5M $9.8M
Free Cash Flow -$511.2M -$452.9M -$197.2M -$83.6M -$30.3M
BPMC
Sector
Market Cap
$5.9B
$43.6M
Price % of 52-Week High
75.68%
47.61%
Dividend Yield
0%
0%
Shareholder Yield
-1.42%
-0.67%
1-Year Price Total Return
5.72%
-34.6%
Beta (5-Year)
0.616
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $95.93
200-day SMA
Sell
Level $98.75
Bollinger Bands (100)
Sell
Level 87.01 - 104.13
Chaikin Money Flow
Buy
Level 19.4M
20-day SMA
Sell
Level $105.27
Relative Strength Index (RSI14)
Sell
Level 34.05
ADX Line
Sell
Level 31.53
Williams %R
Buy
Level -94.3585
50-day SMA
Sell
Level $99.51
MACD (12, 26)
Sell
Level -2.63
25-day Aroon Oscillator
Sell
Level -64
On Balance Volume
Neutral
Level 17.1M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (1.8573)
Sell
CA Score (Annual)
Level (-1.6858)
Sell
Beneish M-Score (Annual)
Level (-1.1146)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (5.1911)
Sell
Piotroski F Score (Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Stock Forecast FAQ

In the current month, BPMC has received 9 Buy ratings 5 Hold ratings, and 1 Sell ratings. The BPMC average analyst price target in the past 3 months is $126.79.

  • Where Will Blueprint Medicines Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Blueprint Medicines share price will rise to $126.79 per share over the next 12 months.

  • What Do Analysts Say About Blueprint Medicines?

    Analysts are divided on their view about Blueprint Medicines share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Blueprint Medicines is a Sell and believe this share price will drop from its current level to $83.00.

  • What Is Blueprint Medicines's Price Target?

    The price target for Blueprint Medicines over the next 1-year time period is forecast to be $126.79 according to 15 Wall Street analysts, 9 of them rate the stock a Buy, 1 rates the stock a Sell, and 5 analysts rate the stock a Hold.

  • Is BPMC A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Blueprint Medicines is a Buy. 9 of 15 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of BPMC?

    You can purchase shares of Blueprint Medicines via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Blueprint Medicines shares.

  • What Is The Blueprint Medicines Share Price Today?

    Blueprint Medicines was last trading at $92.23 per share. This represents the most recent stock quote for Blueprint Medicines. Yesterday, Blueprint Medicines closed at $92.25 per share.

  • How To Buy Blueprint Medicines Stock Online?

    In order to purchase Blueprint Medicines stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Is PFE the Best Dividend Play in Its Industry?
Is PFE the Best Dividend Play in Its Industry?

By their inherent nature, established pharma companies face a demand…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock